Brought to you by 
Eisai options M's Science's depression/stroke compound SA4503
10 Apr 2008
Executive Summary
Japanese cancer and CNS drug development biotech M's Science has licensed Eisai an option to its SA4503, which is in Phase II for major depression and motor dysfunction following a stroke.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai options M's Science's depression/stroke compound SA4503
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice